Swiss drug manufacturer Novartis will acquire IFM Tre , a subsidiary of US firm IF ##H , for $ 500 m , with potentially $ 1.3bn offered in milestone markets . IFM Tre is developing nonalcoholic steatohepatitis ( NASH ) therapy IFM-2427 , a treatment aimed at fatty acid disease , which is becoming more common , alongside Type 2 diabetes and obesity , and could become the first to secure regulatory approval . The market for NASH drugs could be worth up to $ 21.5bn by 2025 , according to ResearchAndMarkets.com .
Swiss drug manufacturer Novartis will acquire IFM Tre, a subsidiary of US firm IFM Therapeutics, for $310m, with potentially $1.3bn offered in milestone payments. IFM Tre is developing nonalcoholic steatohepatitis (NASH) therapy IFM-2427, a treatment aimed at fatty liver disease, which is becoming more common, alongside Type 2 diabetes and obesity, and could become the first to secure regulatory approval. The market for NASH drugs could be worth up to $21.5bn by 2025, according to ResearchAndMarkets.com.